Skip to main content
Delfa

← All assets

Remternetug

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

3

Recruiting

2

Completed

3

Sites

342

Countries

17

Endpoints

39

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 39 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
2
Phase 2/3
2
Phase 3
2

Trials by status

Recruiting
2
Active, not recruiting
1
Completed
3

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Amyloid biomarkers
11
Safety / tolerability / PK
10
Other (unclassified)
5
Memory
4
Fluid / digital biomarkers
4
Global cognition
3
Function / daily living
1
Disease progression
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 7 of 39 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Phosphorylated tau 217 (p-tau217)Fluid/digital

2

Montreal Cognitive Assessment (MoCA)Cognition

1

ADCS-Activities of Daily Living (ADCS-ADL)Function

1

Amyloid PET CentiloidAmyloid

1

Neurofilament light (NfL)Progression

1

Mini-Mental State Examination (MMSE)Cognition

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT06653153A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

Remternetug

Alzheimer’s disease

Amyloid biomarker requiredPh 3Active, not recruiting262Apr 2029-
NCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Remternetug

Alzheimer’s disease

MMSE 20-30Ph 3Completed76Apr 2024-
DIAN-TUA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Remternetug

Alzheimer’s disease

PSEN1/PSEN2/APP mutation requiredPh 2/3Recruiting35Mar 203413
DIAN-TU-002A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Remternetug

Alzheimer’s disease

PSEN1/PSEN2/APP mutation requiredPh 2/3Recruiting35Mar 203416
NCT04451408A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

Remternetug

Alzheimer’s disease

MCI due to ADPh 1Completed13Nov 2024-
NCT03720548A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

Remternetug

Alzheimer’s disease

mild-to-moderate ADPh 1Completed11May 2019-

Showing 1-6 of 6 trials